While there is strong evidence that ULTs are efficacious when used appropriately, their use in gout is too often characterized by poor quality of care and suboptimal patient outcomes. For that reason, a majority of gout patients receiving ULT fail to reach serum urate concentrations <6.0 mg/dl, a threshold associated with mproved outcomes. Although approved at daily doses as high as 800 mg per day, the modal daily dose of allopurinol (accounting for more than 95% of all ULT prescriptions) is 300 mg. Taken together, these data suggest that the current paradigm for gout treatment fails most patients and that novel approaches to health care delivery in chronic gout are needed. We propose a Type 2 translational research project aimed at adopting best practices for the management of gout in a community setting. This project fulfills the definition of Type 2 translational research, which is described by the Institute of Medicine (IOM) as 'research moving discovery from the bedside to community practice'. The IOM has defined deficiencies in medical care as the """"""""quality chasm"""""""", and we have highlighted that a quality chasm in gout exists. The overarching goal of our project is to identify best practices in gout and hyperuricemia management, translate these evidence-based practices into a highly generalizable strategy for optimal delivery of gout care, and implement and evaluate such a strategy in a large, population-based healthcare setting. With the use of novel and readily-accessible technology, we will examine the use of a novel, large-scale, and relatively low-cost pharmacy-based intervention, with the goal of optimizing ULT in chronic gout treatment.
The Specific Aims of our proposal are to: SA1. Using a rigorous randomized controlled study design, compare the effectiveness of a novel pharmacy-based Centralized """"""""virtual"""""""" Gout Clinic (CGC) that incorporates protocol-driven care with usual care in the treatment of chronic gout. SA2. Compare adherence to allopurinol administered through the CGC with administration,in usual care. We hypothesize that a novel CGC incorporating protocol-driven care with the administration of allopurinol in chronic gout will be significantly more effective and will be associated with greater treatment adherence than usual care.
We will examine the effectiveness of a highly novel Centralized Gout Clinic (CGC) in chronic gout management compared to usual care. Working with a large national healthcare system. Kaiser Permanente of Southern California, the CGC will be administered by a centralized pharmacy with patient communications facilitated through the use of an Interactive Voice Response System (IVRS). Given the 'real-life'context in which this study will be conducted, we anticipate that our findings will be highly generalizable and readily portable for translation into other patient populations to optimize gout management and long-term outcomes related to hyperuricemia.
|Ryan, Evan M; Duryee, Michael J; Hollins, Andrew et al. (2018) Antioxidant properties of citric acid interfere with the uricase-based measurement of circulating uric acid. J Pharm Biomed Anal 164:460-466|
|Melles, Ronald B; Jorge, April M; Marmor, Michael F et al. (2018) Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016. Clin Rheumatol 37:1853-1859|
|Bursill, David; Taylor, William J; Terkeltaub, Robert et al. (2018) Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout. Arthritis Care Res (Hoboken) :|
|Jorge, April; Wallace, Zachary S; Zhang, Yuqing et al. (2018) All-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease due to Lupus Nephritis from 1995 to 2014. Arthritis Rheumatol :|
|Choi, Hyon; Neogi, Tuhina; Stamp, Lisa et al. (2018) New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis Rheumatol 70:1702-1709|
|McWherter, Charles; Choi, Yun-Jung; Serrano, Ramon L et al. (2018) Arhalofenate acid inhibits monosodium urate crystal-induced inflammatory responses through activation of AMP-activated protein kinase (AMPK) signaling. Arthritis Res Ther 20:204|
|Sun, Mengying; Vazquez, Ana I; Reynolds, Richard J et al. (2018) Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities. Arthritis Res Ther 20:90|
|Mikuls, Ted R; Cheetham, T Craig; Levy, Gerald D et al. (2018) A Pharmacist-Led Intervention to Improve Gout Medication Adherence and Outcomes with Urate Lowering Therapy: A Site Randomized Trial. Am J Med :|
|Johnson, Tate M; Register, Kyle A; Schmidt, Cynthia M et al. (2018) Correlation of the Multi-Biomarker Disease Activity Score with Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken) :|
|England, Bryant R; Thiele, Geoffrey M; Anderson, Daniel R et al. (2018) Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ 361:k1036|
Showing the most recent 10 out of 57 publications